Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
11 pending office actions • 10 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Cytiva BioProcess R&D AB has 11 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed across 10 distinct examiners and 10 distinct art units, showing a broad examination footprint rather than concentration in one examination group. For prosecution management, this pattern supports centralized claim-position guidance, with individual responses adapted to the assigned examiner and art unit.
JONES-FOSTER, ERICA NICOLE is the busiest examiner, with 2 pending matters. The remaining work is not concentrated with that examiner, so docket oversight should emphasize consistent issue coding, coordinated disclosure analysis, and timely review across the applications. Biotechnology and pharmaceutical claims may benefit from a common technical narrative, but the assignment pattern indicates that each response should remain specific to its record.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 3 (27%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 2 | 49.4% | +44.0% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| CLARKE, TRENT R | 1 | 42.2% | +24.7% |
| ABDEL LATIF, MAHMOUD MOTAZ | 1 | 80.0% | +0.0% |
| LI, BAO Q | 1 | 75.5% | +26.7% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| NORRIS, CLAIRE A | 1 | 66.0% | +27.9% |
| HUANG, RYAN | 1 | 53.1% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562092 | A METHOD OF SEPARATING BISPECIFIC ANTIBODIES | JONES-FOSTER, ERICA NICOLE | 54d |
| 18845830 | VH3 BINDING POLYPEPTIDES | SHELTON, SYNPHANE LA'SHAWN | — |
| 18719120 | A METHOD FOR SEPARATING SUPERCOILED PLASMID DNA | CLARKE, TRENT R | — |
| 18578251 | A METHOD FOR SEPARATING ADENO-ASSOCIATED VIRUS CAPSIDS, COMPOSITIONS OBTAINED BY SAID METHOD AND USES THEREOF | ABDEL LATIF, MAHMOUD MOTAZ | — |
| 18577446 | METHOD FOR VIRUS CAPTURE | LI, BAO Q | — |
| 18555848 | IMPROVED PROTEIN PURIFICATION | EIX, EMILY FAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17608940 | A CHROMATOGRAPHY DEVICE | NORRIS, CLAIRE A | 12d |
| 17607747 | METHOD FOR PURIFICATION OF PLASMA PROTEINS | JONES-FOSTER, ERICA NICOLE | 22d |
| 18562092 | A METHOD OF SEPARATING BISPECIFIC ANTIBODIES | JONES-FOSTER, ERICA NICOLE | 54d |
| 17741394 | CHROMATOGRAPHY MEDIUM | FAN, LYNN Y | 72d |
| 18719120 | A METHOD FOR SEPARATING SUPERCOILED PLASMID DNA | CLARKE, TRENT R | — |
| 18577446 | METHOD FOR VIRUS CAPTURE | LI, BAO Q | — |
| 18555848 | IMPROVED PROTEIN PURIFICATION | EIX, EMILY FAY | — |
| 18354413 | Method of Cleaning and/or Sanitizing a Separation Matrix | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 2 |
| 1652 | 1 |
| 1651 | 1 |
| 1638 | 1 |
| 1671 | 1 |
| 1653 | 1 |
| 1645 | 1 |
| 1759 | 1 |
| 1779 | 1 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845830 | VH3 BINDING POLYPEPTIDES | SHELTON, SYNPHANE LA'SHAWN | 1652 | §101§102§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18719120 | A METHOD FOR SEPARATING SUPERCOILED PLASMID DNA | CLARKE, TRENT R | 1651 | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18578251 | A METHOD FOR SEPARATING ADENO-ASSOCIATED VIRUS CAPSIDS, COMPOSITIONS OBTAINED BY SAID METHOD AND USES THEREOF | ABDEL LATIF, MAHMOUD MOTAZ | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18577446 | METHOD FOR VIRUS CAPTURE | LI, BAO Q | 1671 | §102§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18562092 | A METHOD OF SEPARATING BISPECIFIC ANTIBODIES | JONES-FOSTER, ERICA NICOLE | 1656 | §102§112 | Non-Final OA | 54d | Pending | Nov 17, 2023 |
| 18555848 | IMPROVED PROTEIN PURIFICATION | EIX, EMILY FAY | 1653 | §102§103§112 | Final Rejection | — | Pending | Oct 17, 2023 |
| 18354413 | Method of Cleaning and/or Sanitizing a Separation Matrix | GANGLE, BRIAN J | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 17741394 | CHROMATOGRAPHY MEDIUM | FAN, LYNN Y | 1759 | DP | Final Rejection | 72d | Pending | May 10, 2022 |
| 17608940 | A CHROMATOGRAPHY DEVICE | NORRIS, CLAIRE A | 1779 | §103 | Non-Final OA | 12d | Pending | Nov 04, 2021 |
| 17607747 | METHOD FOR PURIFICATION OF PLASMA PROTEINS | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | 22d | Pending | Oct 29, 2021 |
| 14649227 | Method for Cleaning of Packed Bed Chromatography Columns | HUANG, RYAN | 1777 | §103 | Non-Final OA | — | Pending | Jun 03, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytiva BioProcess R&D AB has 11 pending office actions as of October 2026, spread across 10 art units and 10 examiners.
Erica Nicole Jones-Foster has the most, with 2 of Cytiva BioProcess R&D AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
